Literature DB >> 20143463

Celecoxib inhibits Helicobacter pylori colonization-related factors.

Jing Wang1, Wei-Hong Wang, Jiang Li, Fang-Xun Liu.   

Abstract

AIM: To investigate the effect of celecoxib, a selective COX-2 inhibitor, on Helicobacter pylori (H. pylori) colonization-related factors and its mechanism.
METHODS: After co-incubation with celecoxib, morphology of H. pylori strain 26695 was observed under a transmission electron microscope. Flagella motility was assessed by stab agar motility test. Adherence of H. pylori to AGS cells was determined by enzyme linked immunosorbent assay. Levels of mRNA expression in flagellar genes (flaA, flaB), urease genes (ureA, ureB) and adhesin genes (babA, sabA, alpA, alpB, hpaA, hopZ) were measured by real-time polymerase chain reaction.
RESULTS: Separation and non-integrity of bacterial cell wall, rarefaction and asymmetry of cytoplasm, and even lysis of H. pylori were observed in the presence of celecoxib. When H. pylori strains were incubated in the presence of celecoxib, their flagellar motility and adherence to AGS cells were inhibited. The expression of ureA, ureB, babA, sabA, alpA, alpB, hpaA, hopZ was up-regulated while the expression of flaA, flaB was down-regulated in the presence of celecoxib.
CONCLUSION: Celecoxib inhibits flagellar motility and adherence of H. pylori to AGS cells, and destructs their normal structure in vitro.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20143463      PMCID: PMC2825331          DOI: 10.3748/wjg.v16.i7.846

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  45 in total

1.  Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial.

Authors:  Francis K L Chan; K F To; Justin C Y Wu; M Y Yung; W K Leung; Timothy Kwok; Y Hui; Henry L Y Chan; Cynthia S Y Chan; Elsie Hui; Jean Woo; Joseph J Y Sung
Journal:  Lancet       Date:  2002-01-05       Impact factor: 79.321

2.  Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis.

Authors:  Jia Qing Huang; Subbaramiah Sridhar; Richard H Hunt
Journal:  Lancet       Date:  2002-01-05       Impact factor: 79.321

3.  Non-steroidal anti-inflammatory drugs have bacteriostatic and bactericidal activity against Helicobacter pylori.

Authors:  Haim Shirin; Steven F Moss; Sandy Kancherla; Kevin Kancherla; Peter R Holt; I Bernard Weinstein; Emilia M Sordillo
Journal:  J Gastroenterol Hepatol       Date:  2006-09       Impact factor: 4.029

4.  Long-term nonsteroidal anti-inflammatory drug use and gastroduodenal injury: the role of Helicobacter pylori.

Authors:  D S Loeb; N J Talley; D A Ahlquist; H A Carpenter; A R Zinsmeister
Journal:  Gastroenterology       Date:  1992-06       Impact factor: 22.682

5.  Essential role of urease in pathogenesis of gastritis induced by Helicobacter pylori in gnotobiotic piglets.

Authors:  K A Eaton; C L Brooks; D R Morgan; S Krakowka
Journal:  Infect Immun       Date:  1991-07       Impact factor: 3.441

6.  Helicobacter pylori associated chronic gastritis and peptic ulceration in patients taking non-steroidal anti-inflammatory drugs.

Authors:  T M Shallcross; B J Rathbone; J I Wyatt; R V Heatley
Journal:  Aliment Pharmacol Ther       Date:  1990-10       Impact factor: 8.171

Review 7.  Helicobacter pylori motility.

Authors:  P W O'Toole; M C Lane; S Porwollik
Journal:  Microbes Infect       Date:  2000-08       Impact factor: 2.700

Review 8.  Non-steroidal anti-inflammatory drug use and the risk of gastric cancer: a systematic review and meta-analysis.

Authors:  Wei Hong Wang; Jia Qing Huang; Ge Fan Zheng; Shiu Kum Lam; Johan Karlberg; Benjamin Chun-Yu Wong
Journal:  J Natl Cancer Inst       Date:  2003-12-03       Impact factor: 13.506

9.  Severe gastric mucosal damage induced by NSAIDs in healthy subjects is associated with Helicobacter pylori infection and high levels of serum pepsinogens.

Authors:  L Santucci; S Fiorucci; L Patoia; F M Di Matteo; P M Brunori; A Morelli
Journal:  Dig Dis Sci       Date:  1995-09       Impact factor: 3.199

10.  Effect of cyclo-oxygenase inhibitors on Helicobacter pylori susceptibility to metronidazole and clarithromycin.

Authors:  Q Gu; H H-X Xia; W H Wang; J D Wang; W M Wong; A O O Chan; M F Yuen; S K Lam; H K-L Cheung; X G Liu; B C-Y Wong
Journal:  Aliment Pharmacol Ther       Date:  2004-09-15       Impact factor: 8.171

View more
  5 in total

Review 1.  Antimicrobial Effects of Antipyretics.

Authors:  Petra Zimmermann; Nigel Curtis
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

2.  Anti-LeY antibody enhances therapeutic efficacy of celecoxib against gastric cancer by downregulation of MAPKs/COX-2 signaling pathway: correlation with clinical study.

Authors:  Faisal Aziz; Xuesong Yang; Xiaoqi Wang; Qiu Yan
Journal:  J Cancer Res Clin Oncol       Date:  2014-12-20       Impact factor: 4.553

3.  Nimesulide inhibits pathogenic fungi: PGE2-dependent mechanisms.

Authors:  Rafaelle Fonseca de Matos; Lúcia Carla Vasconcelos Mendonça; Kaira Geiliane da Silva Souza; Adriana Aparecida Durães Fonseca; Elaine Mirla Souza Costa; Marcus Vinicius Dias de Lima; José Maria Dos Santos Vieira; Mioni Thielli Figueiredo Magalhães de Brito; Marta Chagas Monteiro
Journal:  Folia Microbiol (Praha)       Date:  2016-11-19       Impact factor: 2.099

4.  Inhibitory effect of piperine on Helicobacter pylori growth and adhesion to gastric adenocarcinoma cells.

Authors:  Nagendran Tharmalingam; Sa-Hyun Kim; Min Park; Hyun Jun Woo; Hyun Woo Kim; Ji Yeong Yang; Ki-Jong Rhee; Jong Bae Kim
Journal:  Infect Agent Cancer       Date:  2014-12-16       Impact factor: 2.965

5.  Antimicrobial Effect of a Proteolytic Enzyme From the Fruits of Solanum granuloso-leprosum (Dunal) Against Helicobacter pylori.

Authors:  Ángel Gabriel Salinas Ibáñez; Diego Vallés; Mauricio Adaro; Sonia Barberis; Alba E Vega
Journal:  Front Nutr       Date:  2021-12-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.